Lab Reference Library / Lp-PLA2 Activity
Advanced & Specialty
Lp-PLA2 Activity
Lp-PLA2 · Lipoprotein-Associated Phospholipase A2 · PLAC TestReference range, optimal functional medicine levels, and why Lp-PLA2 activity measures vascular wall-specific inflammation rather than systemic inflammation, making it the most specific available marker for oxidized LDL-driven arterial plaque inflammation and unstable plaque vulnerability independent of hs-CRP.
Vascular InflammationCardiovascular Risk
Standard RangeBelow 225 nmol/min/mL
FM OptimalBelow 150 nmol/min/mL
Elevated RiskAbove 225 nmol/min/mL
Unitsnmol/min/mL
← Back to Lab Reference Library
Category: Advanced & Specialty | Also known as: Lipoprotein-Associated Phospholipase A2, PLAC Test, Lp-PLA2 Mass
1. What This Test Measures
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme produced primarily by macrophages, monocytes, and T lymphocytes that has become established as a vascular-specific biomarker of atherosclerotic plaque inflammation. In the circulation, Lp-PLA2 is transported primarily on LDL particles (approximately 70%) and to a lesser extent on HDL and VLDL. When LDL particles penetrate the arterial wall and are oxidized, the Lp-PLA2 they carry hydrolyzes the oxidized phospholipids within the plaque, generating two highly bioactive products: lysophosphatidylcholine (lyso-PC) and oxidized non-esterified fatty acids. Both products are potent inducers of endothelial dysfunction, macrophage recruitment, and foam cell formation, the cellular events that destabilize atherosclerotic plaques and increase rupture risk.
This mechanism makes Lp-PLA2 fundamentally different from general inflammatory markers like hs-CRP. While hs-CRP reflects systemic inflammation from any source, Lp-PLA2 activity is generated within the plaque itself and reflects vascular inflammation directly. Lp-PLA2 is an independent predictor of myocardial infarction, ischemic stroke, and coronary heart disease death in multiple prospective studies, including the Atherosclerosis Risk in Communities (ARIC) study and the West of Scotland Coronary Prevention Study (WOSCOPS). Critically, this predictive power holds even in patients with low or normal LDL cholesterol, making Lp-PLA2 an important component of comprehensive cardiovascular risk assessment beyond standard lipid panels.
2. Optimal Range and Clinical Thresholds
| Lp-PLA2 Activity (nmol/min/mL) | Cardiovascular Risk Interpretation |
|---|---|
| Below 200 nmol/min/mL | Optimal: low vascular inflammation; low Lp-PLA2-associated risk |
| 200 to 225 nmol/min/mL | Borderline: moderate risk; lifestyle optimization and repeat testing in 6 months |
| 225 to 250 nmol/min/mL | Elevated: increased vascular inflammation; comprehensive cardiovascular risk management |
| Above 250 nmol/min/mL | High risk: significant plaque inflammation and rupture risk; aggressive intervention warranted |
Lp-PLA2 mass (ng/mL) and activity (nmol/min/mL) are two different assay formats with different reference ranges. Confirm which assay was used when interpreting results. The activity assay (PLAC test) has the most robust outcome data. Interpret alongside hs-CRP, oxLDL, apoB, and sdLDL for comprehensive vascular risk stratification.
3. The Mechanism: From Plaque to Event
The Lp-PLA2 pathway connects LDL oxidation, macrophage activation, and plaque instability in a direct mechanistic sequence. Oxidized LDL particles accumulate in the sub-intimal space of arterial walls. The Lp-PLA2 carried on those LDL particles cleaves oxidized phospholipid head groups, releasing lyso-PC. Lyso-PC has four downstream consequences that all promote plaque progression and rupture: it activates endothelial cells to express adhesion molecules that recruit more monocytes into the plaque; it promotes macrophage differentiation into foam cells; it induces apoptosis of smooth muscle cells that would otherwise stabilize the plaque cap; and it stimulates cytokine production that drives further local inflammation.
The net result is a thinner, more inflamed fibrous cap over a larger lipid-rich necrotic core, the classic morphology of a vulnerable plaque. Plaque rupture at this fibrous cap triggers acute thrombus formation and clinical events such as MI or stroke. Lp-PLA2 therefore identifies not just the presence of atherosclerosis but specifically the subset of plaques at highest risk of causing acute cardiovascular events, which is why it adds predictive value beyond standard lipid testing.
4. How to Reduce Lp-PLA2
Nutritional Interventions
- Omega-3 fatty acids (EPA+DHA): 2 to 4 g/day reduces Lp-PLA2 activity significantly; EPA is particularly potent; pharmaceutical-grade omega-3s (icosapentaenoic acid) have the strongest evidence
- Reduce oxidized LDL drivers: eliminate industrial seed oils (high omega-6); increase antioxidant-rich foods (olive oil, polyphenol-rich vegetables) that reduce LDL oxidation and Lp-PLA2 substrate availability
- Niacin (extended-release): reduces Lp-PLA2 alongside LDL and triglyceride lowering; requires medical supervision
- Mediterranean dietary pattern: consistently reduces cardiovascular inflammatory markers including Lp-PLA2 in outcome studies
Pharmacological Options
- Statins: reduce Lp-PLA2 activity approximately 20 to 30% as part of their pleiotropic anti-inflammatory effects, independent of LDL lowering
- Fibrates: modest Lp-PLA2 reduction; primarily used when triglycerides are also elevated
- Aspirin: low-dose aspirin does not significantly reduce Lp-PLA2 activity; anti-platelet effect is a separate mechanism
- PCSK9 inhibitors: reduce LDL and Lp-PLA2 in high-risk patients; used when statins are insufficient or not tolerated
Lifestyle and Monitoring
- Aerobic exercise reduces systemic and vascular inflammation; aim for 150 minutes moderate intensity weekly
- Smoking cessation: smoking dramatically increases LDL oxidation and Lp-PLA2 substrate generation
- Weight loss in overweight patients reduces circulating inflammatory burden and Lp-PLA2 activity
- Retest Lp-PLA2 at 6 months after initiating intervention to confirm response
- Pair with annual oxLDL, hs-CRP, and apoB for comprehensive plaque risk monitoring
5. Related Lab Tests
Oxidized LDLDirect measure of the Lp-PLA2 substrate
→
hs-CRPSystemic inflammation; complementary to vascular-specific Lp-PLA2
→
ApoBAtherogenic particle count; pairs with Lp-PLA2 for full plaque risk picture
→
Small Dense LDLMost oxidation-prone LDL fraction; highest Lp-PLA2 association
→
6. Clinical Perspective
Clinical Perspective
Lp-PLA2 is the test that closes the gap between a clean lipid panel and a real MI. I have had patients with an LDL of 88 mg/dL and an Lp-PLA2 of 272 nmol/min/mL, and that combination tells me there is active plaque-level inflammation happening right now despite a cholesterol number that would reassure most physicians. The mechanism is clear: their sdLDL is oxidizing in the arterial wall, Lp-PLA2 is generating lyso-PC from those oxidized particles, and that lyso-PC is destabilizing the fibrous cap. The treatment is also specific: high-dose EPA omega-3s, elimination of the oxidized LDL drivers in the diet, and a statin if the particle burden is high enough. At the six-month retest their Lp-PLA2 is typically down 30 to 40%. That is a measurable reduction in plaque rupture risk that a standard cholesterol panel would have completely missed.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
7. Frequently Asked Questions
What is Lp-PLA2 and why does it matter for heart risk?
Lp-PLA2 is an enzyme produced by macrophages within atherosclerotic plaques. It breaks down oxidized phospholipids to produce lysophosphatidylcholine, a potent pro-inflammatory molecule that promotes foam cell formation, endothelial dysfunction, and plaque instability. High Lp-PLA2 activity identifies vulnerable plaques at high rupture risk, independent of LDL cholesterol levels.
Can I have normal LDL and still have high Lp-PLA2?
Yes, and this is clinically important. Lp-PLA2 is an independent predictor of cardiovascular events. Patients with normal or even low LDL cholesterol can have elevated Lp-PLA2 reflecting active vascular inflammation and vulnerable plaque. This is one reason advanced cardiovascular panels go beyond standard lipid tests.
How do I lower Lp-PLA2?
Omega-3 fatty acids (EPA+DHA) at 2 to 4 g/day reduce Lp-PLA2 activity significantly. Statins reduce Lp-PLA2 approximately 20 to 30% as part of their anti-inflammatory effects. Dietary changes reducing oxidized LDL, smoking cessation, and weight loss also contribute to Lp-PLA2 reduction.
How does Lp-PLA2 differ from hs-CRP?
hs-CRP measures systemic inflammation from any source including infection, autoimmune disease, and obesity. Lp-PLA2 is vascular-specific: it is produced within atherosclerotic plaques and reflects plaque-level inflammation directly. The two markers are complementary and elevated levels of both confer additive cardiovascular risk.
Should Lp-PLA2 be tested if I already have a normal standard lipid panel?
Yes, particularly if you have other cardiovascular risk factors, a family history of early heart disease, metabolic syndrome, or hypertension. Lp-PLA2 adds independent predictive value beyond LDL, HDL, and triglycerides, and identifies vascular inflammation in patients who would otherwise be considered low risk based on standard panels alone.
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Assess Your True Cardiovascular Risk
Lp-PLA2 identifies vascular inflammation beyond standard lipid panels. Schedule a comprehensive cardiovascular risk evaluation with The Lamkin Clinic.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.